Drugs / Cagrilintide D
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07597018 | May 2026 → May 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cagrilintide D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07597018 ↗ |
| Route | Subcutaneous | “Cagrilintide D will be administered subcutaneously.” NCT07597018 ↗ |